King, Valerie A.

From: King, Valerie A.
Sent: Wednesday, February 12, 2003 9:40 AM
To: Venable-Waple, Bristow (RD &E)
Cc: Carchman, Loreen
Subject: RE: MDS 26, 27, & 28

Bristow -
All look good except for a minor revision to PA 27 - In section 1a, "*trans*-3-hydroxycotinine" should be corrected to "*trans*-3'-hydroxycotinine" in both places. Also, the second usage appears to be missing a "-" between the 3 and hydroxycotinine.

Thanks,
Valerie

-----Original Message-----
From: Venable-Waple, Bristow (RD &E)
Sent: Tuesday, February 11, 2003 6:59 PM
To: King, Valerie A.
Cc: Carchman, Loreen
Subject: MDS 26, 27, & 28

I have incorporated the Finance/Purchasing changes into these - we are still waiting on Law Department comments.
<< File: MDS PA 26 - AA01950_1.doc >> << File: MDS PA 27 - PS 27523_4.doc >> << File: MDS PA 28 - AA01949_1.doc >>

M. Bristow Venable-Waple
Sr. Analyst, Programs & Planning
Worldwide Scientific Affairs
OC T3W
x45207
(fax) x43489

PM3006785817

Source: https://www.industrydocuments.ucsf.edu/docs/lzmx0001